Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct:208:108731.
doi: 10.1016/j.lungcan.2025.108731. Epub 2025 Aug 27.

Lineage-specific transcription factor landscape of thymic neuroendocrine tumors

Seiji Omura  1 , Yutaka Kurebayashi  2 , Junko Hamamoto  3 , Hideki Terai  3 , Tomohiro Imoto  4 , Mikito Suzuki  4 , Kazuo Nakagawa  4 , Takahiro Suzuki  5 , Takao Shigenobu  5 , Akira Yoshizu  5 , Chihaya Maeda  6 , Masahiro Kaji  6 , Yu Okubo  1 , Shigeki Suzuki  1 , Kyohei Masai  1 , Kaoru Kaseda  1 , Koichi Fukunaga  3 , Hiroyuki Yasuda  7 , Keisuke Asakura  1
Affiliations
Free article

Lineage-specific transcription factor landscape of thymic neuroendocrine tumors

Seiji Omura et al. Lung Cancer. 2025 Oct.
Free article

Abstract

Introduction: Thymic neuroendocrine tumors (TNETs) are rare malignancies characterized by aggressive clinical behavior and limited therapeutic options. In small cell lung cancer (SCLC), molecular subtypes based on the expression of lineage-defining transcription factors (TFs)-ASCL1, NEUROD1, POU2F3, and YAP1-have been proposed. However, the TF landscape of TNETs remains poorly defined. Given the pathological similarities among neuroendocrine tumors across organs, we aimed to investigate whether the TF-based classification system used in SCLC is applicable to TNETs.

Methods: Sixteen pathologically confirmed TNETs-including large cell neuroendocrine carcinoma (LCNEC), thymic small cell carcinoma (TSCC), atypical carcinoid (AC), and typical carcinoid (TC)-were retrospectively analyzed. Immunohistochemistry was performed to evaluate classical neuroendocrine (NE) markers (synaptophysin, chromogranin A, CD56) and TFs (ASCL1, NEUROD1, POU2F3, YAP1). H-scores were calculated, and tumors were categorized according to TFs expression profiles.

Results: Synaptophysin was strongly expressed in all cases, while chromogranin A and CD56 showed variable expression, with reduced levels in LCNEC and TSCC. The combined NE score was significantly higher in carcinoid tumors compared to LCNEC and TSCC. For TFs, ASCL1 expression was observed in 93.8 % of cases, whereas NEUROD1 and POU2F3 were rarely or not expressed. YAP1 expression was confined to LCNEC cases, all of which co-expressed ASCL1 and YAP1. Based on H-scores, TNETs were classified into three subgroups: (1) ASCL1-positive/YAP1-negative (n = 12, 75 %), (2) ASCL1/YAP1 double-positive (n = 3, 19 %), and (3) double-negative (n = 1, 6 %).

Conclusion: This study reveals molecular heterogeneity among TNETs. Notably, ASCL1 and YAP1 co-expression characterizes all LCNEC cases, making a distinct TF landscape in high-grade TNETs.

Keywords: ASCL1; Immunohistochemistry; Molecular classification; Thymic neuroendocrine tumors; YAP1.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.